AQP4 and multiple sclerosis: In contrast to Disease modification therapy for multiple sclerosis, sequential treatment of NMOSD is required to prevent recurrence, so patients with AQP-4 antibody positive NMOSD or those with AQP-4 antibody negative NMOSD should be treated with immunosuppressant therapy, which actively reduces the annual recurrence rate, the degree of disability accumulation, and improves the prognosis.